290 Risankizumab (RZB) for active psoriatic arthritis (PsA): Integrated subgroup analysis from 2 double-blind, placebo-controlled, phase 3 studies (KEEPsAKE 1 and KEEPsAKE 2)

Abstract

Objective: Report proportion of patients (pts) with active PsA treated with RZB vs placebo (PBO) who achieved ≥20% improvement in American College of Rheumatology criteria (ACR20) by baseline demographics and by concomitant or prior medication use subgroups. RZB specifically inhibits the p19 subunit of cytokine IL-23. KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) are ongoing, multicenter, randomized, double-blind, PBO-controlled, phase 3 studies. Pts with active PsA with an inadequate response or intolerance to conventional synthetic disease-modifying, anti-rheumatic drug (csDMARD; KEEPsAKE 1 and 2) and/or biologic therapy (KEEPsAKE 2) received RZB 150 mg or PBO (1:1).